169 related articles for article (PubMed ID: 22753696)
1. Efficacy of sequential treatment with sunitinib-everolimus in an orthotopic mouse model of renal cell carcinoma.
Larkin J; Esser N; Calvo E; Tsuchihashi Z; Fiedler U; Graeser R; Kim D
Anticancer Res; 2012 Jul; 32(7):2399-406. PubMed ID: 22753696
[TBL] [Abstract][Full Text] [Related]
2. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
Di Lorenzo G; Buonerba C; Federico P; Rescigno P; Milella M; Ortega C; Aieta M; D'Aniello C; Longo N; Felici A; Ruggeri EM; Palmieri G; Imbimbo C; Aglietta M; De Placido S; Mirone V
Eur Urol; 2010 Dec; 58(6):906-11. PubMed ID: 20884115
[TBL] [Abstract][Full Text] [Related]
3. Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer.
Rosa R; Damiano V; Nappi L; Formisano L; Massari F; Scarpa A; Martignoni G; Bianco R; Tortora G
Br J Cancer; 2013 Aug; 109(3):686-93. PubMed ID: 23839492
[TBL] [Abstract][Full Text] [Related]
4. Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinoma.
Dos Santos C; Tijeras-Raballand A; Serova M; Sebbagh S; Slimane K; Faivre S; de Gramont A; Raymond E
Br J Cancer; 2015 Jan; 112(1):86-94. PubMed ID: 25422908
[TBL] [Abstract][Full Text] [Related]
5. Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients.
Levy A; Menard J; Albiges L; Loriot Y; Di Palma M; Fizazi K; Escudier B
Eur J Cancer; 2013 May; 49(8):1898-904. PubMed ID: 23490648
[TBL] [Abstract][Full Text] [Related]
6. More than 4 years of progression-free survival in a patient with metastatic renal cell carcinoma treated sequentially with sunitinib, everolimus, sorafenib, and temsirolimus.
Oudard S
Anticancer Res; 2010 Dec; 30(12):5223-5. PubMed ID: 21187517
[TBL] [Abstract][Full Text] [Related]
7. [Metastatic renal cell cancer in Germany in 2010. Impact of different target therapies].
Siebels M; Hegele A; Varga Z; Oberneder R; Doehn C; Heinzer H;
Urologe A; 2011 Sep; 50(9):1110-7. PubMed ID: 21559917
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells.
D'Amato C; Rosa R; Marciano R; D'Amato V; Formisano L; Nappi L; Raimondo L; Di Mauro C; Servetto A; Fulciniti F; Cipolletta A; Bianco C; Ciardiello F; Veneziani BM; De Placido S; Bianco R
Br J Cancer; 2014 Sep; 111(6):1168-79. PubMed ID: 25093491
[TBL] [Abstract][Full Text] [Related]
9. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma.
Motzer RJ; Barrios CH; Kim TM; Falcon S; Cosgriff T; Harker WG; Srimuninnimit V; Pittman K; Sabbatini R; Rha SY; Flaig TW; Page R; Bavbek S; Beck JT; Patel P; Cheung FY; Yadav S; Schiff EM; Wang X; Niolat J; Sellami D; Anak O; Knox JJ
J Clin Oncol; 2014 Sep; 32(25):2765-72. PubMed ID: 25049330
[TBL] [Abstract][Full Text] [Related]
10. Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma.
Molina AM; Feldman DR; Voss MH; Ginsberg MS; Baum MS; Brocks DR; Fischer PM; Trinos MJ; Patil S; Motzer RJ
Cancer; 2012 Apr; 118(7):1868-76. PubMed ID: 21898375
[TBL] [Abstract][Full Text] [Related]
11. EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma.
Davis ID; Long A; Yip S; Espinoza D; Thompson JF; Kichenadasse G; Harrison M; Lowenthal RM; Pavlakis N; Azad A; Kannourakis G; Steer C; Goldstein D; Shapiro J; Harvie R; Jovanovic L; Hudson AL; Nelson CC; Stockler MR; Martin A
Ann Oncol; 2015 Jun; 26(6):1118-1123. PubMed ID: 25701452
[TBL] [Abstract][Full Text] [Related]
12. Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors.
Busch J; Seidel C; Kempkensteffen C; Johannsen M; Wolff I; Hinz S; Magheli A; Miller K; Grünwald V; Weikert S
Eur Urol; 2011 Dec; 60(6):1163-70. PubMed ID: 21802830
[TBL] [Abstract][Full Text] [Related]
13. Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.
Bellmunt J; Pons F; Foreshew A; Fay AP; Powles T; Porta C; Bracarda S; Lampron ME; Cerbone L; Sternberg CN; Hutson TE; Choueiri TK
Clin Genitourin Cancer; 2014 Aug; 12(4):262-9. PubMed ID: 24795159
[TBL] [Abstract][Full Text] [Related]
14. Chromophobe renal cell carcinoma with prolonged response to sequential sunitinib and everolimus.
Larkin JM; Fisher RA; Pickering LM; Sohaib SA; Ghosn M; Christmas T; Cordiner RL; Gore ME
J Clin Oncol; 2011 Mar; 29(9):e241-2. PubMed ID: 21245426
[No Abstract] [Full Text] [Related]
15. Sunitinib re-challenge in metastatic renal cell carcinoma treated sequentially with tyrosine kinase inhibitors and everolimus.
Paule B; Brion N
Anticancer Res; 2011 Oct; 31(10):3507-10. PubMed ID: 21965770
[TBL] [Abstract][Full Text] [Related]
16. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
17. Second-line treatment outcomes after first-line sunitinib therapy in metastatic renal cell carcinoma.
Chen CC; Hess GP; Liu Z; Gesme DH; Agarwala SS; Garay CC; Hill JW; Guo A
Clin Genitourin Cancer; 2012 Dec; 10(4):256-61. PubMed ID: 22682982
[TBL] [Abstract][Full Text] [Related]
18. Therapy of mRCC beyond mTOR-inhibition in clinical practice: results of a retrospective analysis.
Maute L; Grünwald V; Weikert S; Kube U; Gauler T; Kahl C; Burkholder I; Bergmann L
J Cancer Res Clin Oncol; 2014 May; 140(5):823-7. PubMed ID: 24556802
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib still fi rst-line therapy for metastatic renal cancer.
Bagcchi S
Lancet Oncol; 2014 Sep; 15(10):e420. PubMed ID: 25328943
[No Abstract] [Full Text] [Related]
20. Successful combination of sunitinib and girentuximab in two renal cell carcinoma animal models: a rationale for combination treatment of patients with advanced RCC.
Oosterwijk-Wakka JC; de Weijert MC; Franssen GM; Leenders WP; van der Laak JA; Boerman OC; Mulders PF; Oosterwijk E
Neoplasia; 2015 Feb; 17(2):215-24. PubMed ID: 25748241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
